Ibandronate
Ibandronate is a bisphosphonate medication used to treat and prevent osteoporosis in postmenopausal women, available as an oral tablet and an intravenous injection.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 7 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Ibandronate: Patient Information Guide
A plain-language walkthrough of Ibandronate — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Ibandronate is a bisphosphonate used to strengthen bones in postmenopausal women. The specific approved uses depend on the product form:
- Ibandronate sodium tablets (Boniva, Ibandronate sodium) — oral: Treatment and prevention of osteoporosis in postmenopausal women
- Ibandronate Sodium injection — intravenous: Treatment of osteoporosis in postmenopausal women (not approved for prevention)
- Both forms increase bone mineral density (BMD) and reduce the risk of vertebral (spinal) fractures
- For patients at low risk for fracture, doctors may consider stopping therapy after 3 to 5 years — the optimal duration of treatment has not been definitively established
⚙️How it works▾
Bone is constantly being broken down and rebuilt. After menopause, the breakdown process outpaces rebuilding, causing bone loss. Ibandronate binds strongly to the mineral matrix of bone (called hydroxyapatite) and suppresses the activity of osteoclasts — the cells responsible for breaking down bone tissue. By slowing this process, ibandronate reduces bone loss and allows net bone mass to increase over time, which lowers fracture risk.
💊How it's taken▾
How you take ibandronate depends entirely on which form your doctor has prescribed — the schedules are very different and should not be confused.
- Oral tablet (Boniva, Ibandronate sodium): Taken once a month on the same date each month, first thing in the morning on a completely empty stomach, with a full glass of plain water. Stay upright for at least 60 minutes and wait at least 60 minutes before eating, drinking, or taking other medications. Do not chew or crush the tablet.
- Intravenous injection (Ibandronate Sodium): Given by a healthcare professional once every 3 months — no more frequently. If a dose is missed, reschedule as soon as possible, then continue every 3 months from that new date.
Both forms should be paired with adequate calcium and vitamin D intake — your doctor may recommend a supplement if your diet falls short.
🤒Side effects — in detail▾
The most common side effects reported with ibandronate include:
- Back pain
- Indigestion (dyspepsia) or upset stomach
- Diarrhea
- Headache
- Muscle aches (myalgia)
- Pain in the arms or legs
- Nausea or abdominal pain
- Flu-like symptoms (more common after injection or the first monthly dose)
More serious reactions — including esophageal ulcers, severe jaw pain, unusual thigh bone fractures, severe musculoskeletal pain, and low blood calcium — require prompt medical attention. Contact your doctor if any new or severe symptoms develop.
⚠️Warnings & precautions▾
- Esophageal irritation (tablet only): Ibandronate tablets can cause serious damage to the esophagus (food pipe), including ulcers and erosions. Risk is highest if you lie down after taking it, don't use a full glass of water, or continue taking it after symptoms appear. Stop and call your doctor if you have trouble swallowing, chest pain, or severe heartburn.
- Low blood calcium (hypocalcemia): Ibandronate can worsen low calcium levels. Existing hypocalcemia must be treated before starting therapy. Take calcium and vitamin D as directed.
- Severe bone, joint, or muscle pain: Some people experience incapacitating pain that may start days to months after beginning ibandronate. Symptoms often improve when the drug is stopped.
- Osteonecrosis of the jaw (ONJ): Rare but serious bone damage in the jaw, often linked to dental procedures. Maintain good oral hygiene and tell your dentist you take a bisphosphonate before any dental work.
- Atypical femur fractures: Unusual, low-trauma fractures of the thigh bone have been reported. Report new thigh or groin pain to your doctor promptly.
- Severe kidney impairment: Ibandronate tablets are not recommended if your creatinine clearance (a measure of kidney function) is below 30 mL/min.
🔀What it interacts with▾
Several medications and foods can affect how ibandronate works or increase the risk of side effects:
- Calcium supplements, antacids, and multivitamins: Products containing calcium, magnesium, aluminum, or iron can sharply reduce the absorption of the tablet. Wait at least 60 minutes after taking ibandronate before using these.
- Food and all beverages except plain water: Taking the tablet with food or any drink other than plain water can reduce absorption by up to 90%. Always take it on a completely empty stomach.
- Aspirin and NSAIDs (e.g., ibuprofen, naproxen): Both NSAIDs and bisphosphonates can irritate the stomach and esophagus — using them together increases that risk.
- Bone imaging agents: Bisphosphonates can interfere with bone scans. Let your imaging provider know you take ibandronate.
- Calcium-containing IV solutions (injection form): Ibandronate Sodium injection must not be mixed with calcium-containing intravenous solutions or other IV drugs.
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Do not take ibandronate tablets if you have an esophageal problem that slows swallowing, such as stricture or achalasia
- Do not take ibandronate tablets if you are unable to sit or stand upright for at least 60 minutes
- Do not start ibandronate if you have low blood calcium (hypocalcemia) — treat this first
- Do not take if you have had a serious allergic reaction to ibandronate or any ingredient in the product
- Ibandronate tablets are not recommended if you have severe kidney disease (creatinine clearance below 30 mL/min); let your doctor know your kidney function
- Ibandronate is not intended for use in pregnant women or those who may become pregnant — animal studies showed serious pregnancy risks
- There is no information on ibandronate in human breast milk; the drug is not indicated during breastfeeding
- Safety and effectiveness have not been established in patients under 18
- Older adults can use ibandronate safely, but kidney function should be monitored over time
🚑If you take too much▾
There is no specific antidote for an ibandronate overdose, but taking too much can cause low blood calcium (hypocalcemia), low blood phosphate (hypophosphatemia), and upper gastrointestinal problems such as stomach upset, indigestion, esophagitis, or ulcers. If an overdose of the tablet is suspected, milk or antacids can be given to help bind the drug — but do not induce vomiting, as this could worsen esophageal irritation. The patient should stay fully upright. Dialysis would not be helpful in removing ibandronate from the body.
📡Pharmacodynamics — effects in the body▾
Ibandronate measurably slows the rate at which bone is broken down, as shown by reductions in blood and urine markers of bone breakdown (such as serum CTX). In postmenopausal women, these markers can drop significantly within the first month of tablet treatment and continue to decline for up to 6 months before stabilizing. This slowing of bone turnover leads to a net gain in bone mineral density over time. If ibandronate is stopped, the elevated rate of bone loss associated with menopause returns.
🔬Pharmacokinetics — how your body processes it▾
When taken orally, ibandronate is absorbed in the upper digestive tract, but its oral bioavailability is very low — and drops by about 90% if taken with food or beverages other than plain water, which is why it must be taken on a completely empty stomach. After absorption, 40–50% of the drug that reaches the bloodstream binds rapidly to bone; the rest is excreted unchanged by the kidneys. Ibandronate is not broken down by the liver and does not interact with the liver's drug-processing enzymes. Its apparent terminal half-life (how long it takes the body to clear it from the blood) ranges from roughly 37 to 157 hours for the oral tablet, though it persists in bone tissue much longer. Patients with significantly reduced kidney function have higher drug exposure and may need dose adjustments or avoidance of the drug.
📦How to store it▾
Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F) . Dispense in a tight container .
📄 Written from Ibandronate’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
Supplements & herbs that interact with Ibandronate
23 supplements and herbal products have documented interactions with Ibandronate in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 1
- Moderate · 13
- Minor · 9
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Ibandronate — the kind of thing our pharmacy team would talk through with you at the counter.
What exactly is ibandronate and what is it supposed to do for me? ▾
How do I take the tablet correctly? I've heard there are a lot of rules. ▾
What side effects should I expect, and which ones should make me call the doctor? ▾
Can I take my calcium supplement and vitamins at the same time as ibandronate? ▾
How long will I need to be on this medication? ▾
Is ibandronate safe if I'm planning to get pregnant or am breastfeeding? ▾
Is Ibandronate available over the counter? ▾
When was Ibandronate first available? ▾
Who makes Ibandronate? ▾
💬 Answers drafted from Ibandronate’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Ibandronate comes
Ibandronate is available in 2 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Tablet
How this form is used
- Boniva and Ibandronate sodium tablets are used for the treatment of osteoporosis in postmenopausal women
- Boniva and Ibandronate sodium tablets are used for the prevention of osteoporosis in postmenopausal women
- Boniva and Ibandronate sodium tablets increase bone mineral density and reduce the risk of spinal fractures
- Boniva and Ibandronate sodium tablets are taken once monthly on the same date each month, first thing in the morning
- Swallow the tablet whole with a full glass (6–8 oz) of plain water while sitting or standing upright; do not chew or suck it
- Take at least 60 minutes before the first food, drink (other than plain water), or other medication of the day — including calcium supplements and antacids
- Stay upright (sitting or standing) for at least 60 minutes after taking the tablet; do not lie down
Injection
How this form is used
- Ibandronate Sodium injection is used for the treatment of osteoporosis in postmenopausal women
- Ibandronate Sodium injection increases bone mineral density and reduces the risk of spinal fractures
- Ibandronate Sodium injection is given by a healthcare professional into a vein (intravenously) once every 3 months — do not receive it more frequently than every 3 months
- Ibandronate Sodium injection must not be mixed with calcium-containing IV solutions or other intravenous drugs
- Take supplemental calcium and vitamin D if your dietary intake is inadequate, as directed by your healthcare provider
- If a scheduled Ibandronate Sodium injection dose is missed, have it rescheduled as soon as possible, then continue on the every-3-month schedule from that date
📊 Ibandronate across the U.S. market
How Ibandronate appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (6) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Ibandronate is used
A general measure of how commonly Ibandronate is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Ibandronate is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Ibandronate prescribed? Of the 1,596 medications we measure, Ibandronate ranks #766 by Medicaid prescriptions — more than 52% of them.
Utilization by Ibandronate product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
ibandronic acid 150 MG Oral Tablet
Summed across the 6 of 19 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 904932
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Ibandronate, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 6 of 19 listed Ibandronate NDCs with Medicaid activity.
🔍 Compare Ibandronate products
A representative set of FDA-listed product records for Ibandronate — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 3 mg/3 mL | Intravenous | Accord Healthcare Inc. | ANDA | Find on DailyMed ↗ |
| 3 mg/3 mL | Intravenous | Apotex Corp. × 3 listings | ANDA | View NDC → |
| 3 mg/3 mL | Intravenous | AuroMedics Pharma LLC | ANDA | View NDC → |
| 3 mg/3 mL | Intravenous | Eugia US LLC | ANDA | View NDC → |
| 3 mg/3 mL | Intravenous | Mylan Institutional LLC | ANDA | View NDC → |
| 3 mg/3 mL | Intravenous | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 3 mg/3 mL | Intravenous | TAGI Pharma, Inc. | ANDA | View NDC → |
| 💊Tablet | ||||
| 150 mg | Oral | A-S Medication Solutions | ANDA | View NDC → |
| 150 mg | Oral | Alvogen Inc. × 2 listings | ANDA | View NDC → |
| 150 mg | Oral | Apotex Corp × 3 listings | ANDA | View NDC → |
| 150 mg | — | Apotex Corp. | DRUG FOR FURTHER PROCESSING | View NDC → |
| 150 mg | — | Aurobindo Pharma Limited | DRUG FOR FURTHER PROCESSING | View NDC → |
| 150 mg | Oral | Aurobindo Pharma Limited × 3 listings | ANDA | View NDC → |
| 150 mg | Oral | Bionpharma Inc. × 2 listings | ANDA | View NDC → |
| 150 mg | Oral | Dr. Reddy's Laboratories Limited × 3 listings | ANDA | View NDC → |
| 150 mg | Oral | Genentech, Inc. | NDA | View NDC → |
| 150 mg | Oral | Golden State Medical Supply, Inc. × 3 listings | ANDA | View NDC → |
| 150 mg | Oral | Macleods Pharmaceuticals Limited × 2 listings | ANDA | View NDC → |
| 💊Bulk drug substance | ||||
| 1 kg/kg | — | Apotex Inc. | BULK INGREDIENT | View NDC → |
| 50 kg/50 kg | — | Aurobindo Pharma Limited | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Dr.Reddy's Laboratories Limited × 2 listings | BULK INGREDIENT | View NDC → |
| 15 kg/15 kg | — | Emcure Pharmaceuticals Limited | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Natco Pharma Limited | BULK INGREDIENT | View NDC → |
Showing 37 of 37 products — FDA National Drug Code Directory. See every product, package size and price: browse all 37 Ibandronate NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Ibandronate — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Ibandronate in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Ibandronate went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 115264 3 dose forms · 5 strengths
-
Dose form (SCDF) Injection RxCUI 1659716In current FDA listingsClinical drug / strength (SCD) 3 ML ibandronic acid 1 MG/MLRxCUI 904955 -
Dose form (SCDF) Oral Tablet RxCUI 452852In current FDA listingsClinical drug / strength (SCD) ibandronic acid 150 MGRxCUI 904932ibandronic acid 2.5 MGRxCUI 904936ibandronic acid 50 MGRxCUI 904946 -
Dose form (SCDF) Prefilled Syringe RxCUI 727807No current FDA listingClinical drug / strength (SCD) 3 ML ibandronic acid 1 MG/MLRxCUI 904952
Look up RxCUI 115264 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Ibandronate is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
RxNorm drug class
Ibandronate belongs to the Bisphosphonate class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 7 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Golden State Medical Supply, Inc. is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.